Skip to Content

'
Mary Frances McAleer, MD, PhD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2001 Jefferson Medical College, Philadelphia, PA, MD, Medicine
2001 Thomas Jefferson University, Philadelphia, PA, PHD, Biochemistry and Molecular Biology
1988 Villanova University, Villanova, PA, BS, General Science Honors, General Science Honors

Postgraduate Training

7/2002-8/2006 Residency in Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, Walter J Curran, Jr, MD
7/2001-6/2002 Internship in Transitional Medicine, Albert Einstein Medical Center, Philadelphia, PA, Glenn Eiger, MD

Honors and Awards

2006 NCI Young Investigator's Workshop for Radiation Oncology Travel Award, National Cancer Institute
2005 RSNA Roentgen Research Award, RSNA
2003 ASCO/AACR Methods in Clinical Cancer Research Fellow Award, ASCO/AACR
2001 Harold L. Stewart, M.D.'26 Prize, Thomas Jefferson University, Department of Pathology
1996 National Cancer Institute Summer Research Fellowship, National Cancer Institute
1995-2001 Gibbon Scholar MD/PhD Fellowship, Thomas Jefferson University
1993 Foerderer Fellowship, Thomas Jefferson University
1988-1989 Braddock Award, Pennsylvania State University
1988-1989 National Science Foundation Graduate Fellowship
1988 Da Vinci Award for Academic Excellence, Science Honors, Villanova University

Selected Publications

Peer-Reviewed Original Research Articles
1. McGovern SL, Liao Z, Bucci MK, McAleer MF, Jeter MD, Chang JY, O'Reilly MS, Cox JD, Allen PK, Komaki R.. Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer? Cancer 115(14):3233-42, 7/2009. PMID: 19472405.
2. McAleer MF, Moughan J, Byhardt RW, Cox JD, Sause WT, Komaki R. Does Response to Induction Chemotherapy Predict Survival for Locally Advanced Non-Small-Cell Lung Cancer? Secondary Analysis of RTOG 8804/8808. Int J Radiat Oncol Biol Phys. e-Pub 6/17/2009. PMID: 19540055.
3. McCurdy M, McAleer MF, Wei W, Ezhil M, Johnson V, Khan M, Baker J, Luo D, Ajani J, Guerrero T.. Induction and Concurrent Taxanes Enhance both the Pulmonary Metabolic Radiation Response and the Radiation Pneumonitis Response in Patients with Esophagus Cancer. Int J Radiat Oncol Biol Phys. e-Pub 6/12/2009. PMID: 19525073.
4. Smith GL, Smith BD, Buchholz TA, Liao Z, Jeter M, Swisher SG, Hofstetter WL, Ajani JA, McAleer MF, Komaki R, Cox JD. Patterns of Care and Locoregional Treatment Outcomes in Older Esophageal Cancer Patients: The SEER-Medicare Cohort. Int J Radiat Oncol Biol Phys 74(2). e-Pub 3/14/2009. PMID: 19289262.
5. Starkschall G, Britton K, McAleer MF, Jeter MD, Kaus MR, Bzdusek K, Mohan R, Cox JD. Potential dosimetric benefits of four-dimensional radiation treatment planning. Int J Radiat Oncol Biol Phys 73(5). e-Pub 2/21/2009. PMID: 19231098.
6. Gayed I, Gohar S, Liao Z, McAleer M, Bassett R, Yusuf SW. The clinical implications of myocardial perfusion abnormalities in patients with esophageal or lung cancer after chemoradiation therapy. Int J Cardiovasc Imaging. e-Pub 2/22/2009. PMID: 19234869.
7. Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M, Bucci MK, McAleer MF, Mehran RJ, Roth JA, Komaki R. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 72(4):967-71, 11/15/2008. PMID: 18954709.
8. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Ilson DH, Kleinberg LR, McAleer MF, Meropol NJ, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Swisher SG, Washington MK, Willett C, Wood DE, Wright CD, Yang G, Yang G. Esophageal cancer. J Natl Compr Canc Netw 6(9):818-49, 10/2008. PMID: 18926093.
9. Hazard L, Yang G, McAleer MF, Hayman J, Willett C. Principles and techniques of radiation therapy for esophageal and gastroesophageal junction cancers. J Natl Compr Canc Netw 6(9):870-8, 10/2008. PMID: 18926096.
10. Javeri H, Arora R, Correa AM, Hofstetter WL, Lee JH, Liao Z, McAleer MF, Maru D, Bhutani MS, Swisher SG, Izzo JG, Ajani JA. Influence of Induction Chemotherapy and Class of Cytotoxics on Pathologic Response and Survival after Preoperative Chemoradiation in Patients with Carcinoma of the Esophagus. Cancer 15(113):1302-1308, 9/2008. PMID: 18623381.
11. McAleer MF. Proportion of residual tumor associated with failure after preoperative chemoradiotherapy for locally advanced esophageal cancer. Gastrointest Cancer Res 2(5):261-3, 9/2008. PMCID: PMC2632552.
12. Yaremko BP, Guerrero TM, McAleer MF, Bucci MK, Noyola-Martinez J, Nguyen LT, Balter PA, Guerra R, Komaki R, Liao Z. Determination of respiratory motion for distal esophagus cancer using four-dimensional computed tomography. Int J Radiat Oncol Biol Phys 70(1):145-53, 1/1/2008. e-Pub 9/12/2007. PMID: 17855008.
13. Rice DC, Smythe WR, Liao Z, Guerrero T, Chang JY, McAleer MF, Jeter MD, Correa A, Vaporciyan AA, Liu HH, Komaki R, Forster KM, Stevens CW. Dose-Dependent Pulmonary Toxicity After Postoperative Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma. Int J Radiat Oncol Biol Phys 69(2):350-7, 10/2007. e-Pub 4/2007. PMID: 17467922.
14. McAleer MF, Duffy KT, Davidson WR, Kari G, Dicker AP, Rodeck U, Wickstrom E. Antisense inhibition of cyclin D1 expression is equivalent to flavopiridol for radiosensitization of zebrafish embryos. Int J Radiat Oncol Biol Phys 66(2):546-551, 2006. e-Pub 8/14/2006. PMID: 16904844.
15. Daroczi B, Kari G, McAleer MF, Wolf JC, Rodeck U, Dicker AP. In vivo radioprotection by the fullerene nanoparticle DF-1 as assessed in a zebrafish model. Clin Cancer Res 12(23):7086-7091, 2006. PMID: 17145832.
16. Duffy KT, McAleer MF, Davidson WR, Kari L, Kari C, Liu CG, Farber SA, Cheng KC, Mest JR, Wickstrom E, Dicker AP, Rodeck U. Coordinate control of cell cycle regulatory genes in zebrafish development tested by cyclin D1 knockdown with morpholino phosphorodiamidates and hydroxyprolyl-phosphono peptide nucleic acids. Nucleic Acids Res 33(15):4914-21, 2005. PMCID: PMC1199556.
17. McAleer MF, Tuan RS. Cytotoxicant-induced trophoblast dysfunction and abnormal pregnancy outcomes: role of zinc and metallothionein. Birth Defects Res C Embryo Today 72(4):361-370, 2004. PMID: 15662702.
18. McAleer MF, Davidson C, Davidson WR, Yentzer B, Farber SA, Rodeck U, Dicker AP. Novel use of zebrafish as a vertebrate model to screen radiation protectors and sensitizers. Int J Radiat Oncol Biol Phys 61(1):10-3, 2004. PMID: 15629588.
19. McAleer MF, Tuan RS. Metallothionein overexpression in human trophoblastic cells protects against cadmium-induced apoptosis. In Vitro Molec Toxicol 14(1):25-42, 2001. PMID: 11689154.
20. McAleer MF, Tuan RS. Metallothionein protects against severe oxidative stress-induced apoptosis of human trophoblastic cells. In Vitro Molec Toxicol 14(3):219-231, 2001. PMID: 11846994.
21. Knight D, Wagner C, Jordan RE, McAleer MF, DeRita R, Fass DN, Coller BS, Weisman HF, Ghrayeb J. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. J Molec Immunol 32(16):1271-1281, 1995. PMID: 8559151.

Last updated: 8/20/2009